Plasma metabolite profiles associated with the World Cancer Research Fund/American Institute for Cancer Research lifestyle score and future risk of cardiovascular disease and type 2 diabetes
Authors' conclusion
In an elderly population at high risk of CVD, a set of metabolites was selected as potential metabolites associated with the HL pattern predicting the risk of T2D and, to a lesser extent, CVD. These results support previous findings that some of these metabolites are inversely associated with the risk of T2D and CVD.
Study context
- Population
- Individuals at high cardiovascular risk, aged 55–80y, subset of PREDIMED studyPREDIMED subset
- Participants
- 1,833 individuals
- Exposure
- Metabolite profiles of healthy lifestyle (HL) score and incident T2D and cardiovascular disease (CVD)
- Outcome
- Association of HL-score metabolite profiles with incidence of T2D and CVD
Methodological detailscross-sectional and prospective cohort, elastic net regression, 10-cross-validation, discovery (baseline) and validation (1-year) samples, multivariable Cox regression, Plasma metabolites by LC-MS/MS; 385 known metabolites
- Cross-sectional and prospective cohort
- Elastic net regression
- 10-cross-validation
- Discovery (baseline) and validation (1-year) samples
- Multivariable Cox regression
- Plasma metabolites by LC-MS/MS; 385 known metabolites
Main finding
As reported in the abstract
Baseline metabolite profiles and risk of T2D and CVD (adjusted)
- Metabolites in profile, dichotomous HL
- 24
- Metabolites in profile, continuous HL
- 58
- T2D, dichotomous HL profile: HR
- 0.54, 0.38-0.77 (95% CI)
- T2D, continuous HL profile: HR
- 0.22, 0.11-0.43 (95% CI)
- CVD, dichotomous HL profile: HR
- 0.59, 0.42-0.83 (95% CI)
- CVD, continuous HL profile: HR
- 0.58, 0.31-1.07 (95% CI)
Observational data: associations, not effects.
Further findings
1-year metabolomic profile and risk of T2D and CVD
- Reduction in risk of T2D maintained and of CVD attenuated with 1-year profile
Original publication
Plasma metabolite profiles associated with the World Cancer Research Fund/American Institute for Cancer Research lifestyle score and future risk of cardiovascular disease and type 2 diabetes. Cardiovasc Diabetol. Published 16 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →